Journal article Open Access

Adverse effects of anticancer agents that target the VEGF pathway

Chen, Helen X.; Cleck, Jessica N.


DataCite XML Export

<?xml version='1.0' encoding='utf-8'?>
<resource xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="http://datacite.org/schema/kernel-4" xsi:schemaLocation="http://datacite.org/schema/kernel-4 http://schema.datacite.org/meta/kernel-4.1/metadata.xsd">
  <identifier identifierType="URL">https://zenodo.org/record/1233504</identifier>
  <creators>
    <creator>
      <creatorName>Chen, Helen X.</creatorName>
      <givenName>Helen X.</givenName>
      <familyName>Chen</familyName>
    </creator>
    <creator>
      <creatorName>Cleck, Jessica N.</creatorName>
      <givenName>Jessica N.</givenName>
      <familyName>Cleck</familyName>
    </creator>
  </creators>
  <titles>
    <title>Adverse effects of anticancer agents that target the VEGF pathway</title>
  </titles>
  <publisher>Zenodo</publisher>
  <publicationYear>2009</publicationYear>
  <dates>
    <date dateType="Issued">2009-07-07</date>
  </dates>
  <resourceType resourceTypeGeneral="Text">Journal article</resourceType>
  <alternateIdentifiers>
    <alternateIdentifier alternateIdentifierType="url">https://zenodo.org/record/1233504</alternateIdentifier>
  </alternateIdentifiers>
  <relatedIdentifiers>
    <relatedIdentifier relatedIdentifierType="DOI" relationType="IsIdenticalTo">10.1038/nrclinonc.2009.94</relatedIdentifier>
  </relatedIdentifiers>
  <rightsList>
    <rights rightsURI="http://creativecommons.org/publicdomain/zero/1.0/legalcode">Creative Commons Zero v1.0 Universal</rights>
    <rights rightsURI="info:eu-repo/semantics/openAccess">Open Access</rights>
  </rightsList>
  <descriptions>
    <description descriptionType="Abstract">Antiangiogenic agents that target the VEGF pathway have become an important part of standard therapy in multiple cancer indications. Although most adverse effects of VEGF inhibitors are modest and manageable, some are associated with serious and life-threatening consequences. This Review examines the toxicity profiles of anti-VEGF monoclonal antibodies and small-molecule inhibitors and considers the potential mechanisms of the adverse effects, risk factors, and the implications for patient management.</description>
  </descriptions>
</resource>
81
100
views
downloads
Views 81
Downloads 100
Data volume 43.2 MB
Unique views 74
Unique downloads 88

Share

Cite as